Axar.az
UP

Pfizer seen reaping billions from COVID-19 vaccine market

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

Axar.az reports that for several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.

Now a growing list of governments, including Chile, Germany and Israel, have decided to offer booster doses to older citizens or people with weak immune systems in the face of the fast-spreading Delta variant.

Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.

Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.

The vaccine makers say that evidence of waning antibody levels in vaccinated people after six months, as well as an increasing rate of breakthrough infections in countries hit by the Delta variant, support the need for booster shots.

Date
2021.08.13 / 20:55
Author
Axar.az
Comments
See also

Pfizer has withdrawn a drug at risk for cancer

China administers over 2 bln COVID-19 vaccine doses

EU and AstraZeneca reach deal to end vaccine row

A new strain of the coronavirus is spreading - WHO

Delta variant patients twice as likely need hospital care

5 billion doses of vaccine have been given worldwide

Pfizer COVID-19 vaccine wins full U.S. FDA approval

American expert`s pessimistic statement about COVID-19

WHO sees possibility of naming new coronavirus strains

Pfizer and Moderna vaccines have risen in price

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla